NEW YORK, April 24 - Genaissance Pharmaceuticals said Tuesday it had begun enrolling patients for its clinical trials which will aim to correlate haplotypes with individuals’ reactions to particular drugs.

In its initial study, the company plans to enroll about 600 patients at 60 medical centers in the US to correlate patient haplotypes with the affects of cholesterol lowering drugs. The Statin Response Examined by Genetic HAP Study, or STRENGTH, will look at Lipitor, Zocor, Pravachol, and Baycol. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.